Segall Bryant & Hamill, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Segall Bryant & Hamill, LLC
- $6.35 Billion
- Q1 2025
A detailed history of Segall Bryant & Hamill, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 91,936 shares of CPRX stock, worth $2.26 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
91,936
Previous 80,354
14.41%
Holding current value
$2.26 Million
Previous $1.68 Million
33.0%
% of portfolio
0.04%
Previous 0.02%
Shares
3 transactions
Others Institutions Holding CPRX
# of Institutions
388Shares Held
99.3MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$459 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$208 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$136 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$84 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$76.9 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.52B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...